Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1989 1
1991 1
1994 1
1995 1
2000 2
2001 1
2002 1
2004 1
2005 2
2006 2
2007 1
2011 1
2012 2
2013 2
2014 2
2016 1
2017 1
2018 1
2019 2
2020 2
2021 6
2022 2
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Transformed T-cell Non-Hodgkin Lymphoma"
Page 1
Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan.
Goto H, Kitawaki T, Fujii N, Kato K, Onishi Y, Fukuhara N, Yamauchi T, Toratani K, Kobayashi H, Yoshida S, Shimo M, Onodera K, Senjo H, Onozawa M, Hirata K, Yokota I, Teshima T. Goto H, et al. Int J Clin Oncol. 2023 Jun;28(6):816-826. doi: 10.1007/s10147-023-02334-w. Epub 2023 Apr 18. Int J Clin Oncol. 2023. PMID: 37071252
BACKGROUND: Tisagenlecleucel, an autologous CD19-directed T-cell immunotherapy, can induce a durable response in adult patients with relapsed/refractory (r/r) B-cell lymphoma. METHODS: To elucidate the outcome of chimeric antigen receptor (CAR) T-ce …
BACKGROUND: Tisagenlecleucel, an autologous CD19-directed T-cell immunotherapy, can induce a durable response in adult patient …
Mechanisms of and approaches to overcoming resistance to immunotherapy.
Schultz L, Gardner R. Schultz L, et al. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):226-232. doi: 10.1182/hematology.2019000018. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808880 Free PMC article. Review.
A functional immune system is also required for maximal benefit of immunotherapy, particularly with chimeric antigen receptor (CAR) T-cell therapies. Data are now being produced that may allow for the prospective identification of patients whose immune deficits may …
A functional immune system is also required for maximal benefit of immunotherapy, particularly with chimeric antigen receptor (CAR) T …
Mycosis Fungoides: A 10-year Turkish Experience.
Baykal Selcuk L, Aksu Arica D, Yayli S, Seyman Ü, Bahadir S. Baykal Selcuk L, et al. Acta Dermatovenerol Croat. 2019 Sep;27(3):153-158. Acta Dermatovenerol Croat. 2019. PMID: 31542058
Mycosis fungoides is the most common primary cutaneous T cell lymphoma, characterized by erythematous patches and plaque lesions with slow progression to cutaneous tumors or extracutaneous involvements in some patients. ...Large cell transformation was …
Mycosis fungoides is the most common primary cutaneous T cell lymphoma, characterized by erythematous patches and plaqu …
t(10;12)(q24;q15): A new cytogenetic marker in hematological malignancies.
Bernués M, González T, Corchete LA, Santos S, Durán MA, López-Andrade B, Riso LL, Martínez-Serra J, Ramos R, Iglesias J, Royo I, Rosell J. Bernués M, et al. Cancer Genet. 2022 Jun;264-265:60-65. doi: 10.1016/j.cancergen.2022.03.004. Epub 2022 Mar 26. Cancer Genet. 2022. PMID: 35397254 Review.
The chromosome alteration was observed as a sole karyotype change in the patient with MDS-EB, both at the initial diagnosis and following progression to MDS-EB2. ...The patient with ET, had a normal karyotype at diagnosis and the t(10;12)(q24;q15) translocation emerged as …
The chromosome alteration was observed as a sole karyotype change in the patient with MDS-EB, both at the initial diagnosis and follo …
Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous T-cell lymphoma.
Jones CL, Degasperi A, Grandi V, Amarante TD; Genomics England Research Consortium; Mitchell TJ, Nik-Zainal S, Whittaker SJ. Jones CL, et al. Sci Rep. 2021 Feb 17;11(1):3962. doi: 10.1038/s41598-021-83352-4. Sci Rep. 2021. PMID: 33597573 Free PMC article.
Adult T-cell leukemia-lymphoma was specifically associated with signature 17, which was found to correlate with the IRF4 K59R mutation that is exclusive to Adult T-cell leukemia-lymphoma. ...Analysis of non-Hodgkin's T-cell …
Adult T-cell leukemia-lymphoma was specifically associated with signature 17, which was found to correlate with the IRF …
Blinatumomab consolidation post-autologous stem cell transplantation in patients with diffuse large B-cell lymphoma.
Ghobadi A, Foley NC, Cohen J, Rettig MP, Cashen AF, Gehrs L, Christ S, Street E, Wallace N, Ritchey J, Mehta-Shah N, Westervelt P, Fehniger TA, Kahl B, Bartlett NL, DiPersio JF. Ghobadi A, et al. Blood Adv. 2024 Feb 13;8(3):513-522. doi: 10.1182/bloodadvances.2023011130. Blood Adv. 2024. PMID: 37871306 Free PMC article.
Blinatumomab is a CD3/CD19 bispecific T-cell engager that directs cytotoxic T cells to CD19+ cells. Here, we performed a pilot study of blinatumomab consolidation after auto-SCT for 14 patients with DLBCL or transformed follicular lymphoma. ...At 1 yea …
Blinatumomab is a CD3/CD19 bispecific T-cell engager that directs cytotoxic T cells to CD19+ cells. Here, we performed a pilot …
Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma.
Fried S, Shouval R, Walji M, Flynn JR, Yerushalmi R, Shem-Tov N, Danylesko I, Tomas AA, Fein JA, Devlin SM, Sauter CS, Shah GL, Kedmi M, Jacoby E, Shargian L, Raanani P, Yeshurun M, Perales MA, Nagler A, Avigdor A, Shimoni A. Fried S, et al. Transplant Cell Ther. 2023 Feb;29(2):99-107. doi: 10.1016/j.jtct.2022.10.026. Epub 2022 Nov 5. Transplant Cell Ther. 2023. PMID: 36343892 Free PMC article.
Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy has transformed the care of patients with relapsed/refractory large B cell lymphoma (LBCL). ...In multivariable analyses, pre-HCT elevated lactate dehydrogenase level and transformed …
Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy has transformed the care of patients with relapsed/refractor …
Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R, Mehta N, Migliacci JC, Zelenetz A, Moskowitz A, Lunning M, Moskowitz C, Hamlin P, Horwitz S. Gurion R, et al. Acta Oncol. 2016 May;55(5):561-6. doi: 10.3109/0284186X.2015.1118656. Epub 2016 Apr 4. Acta Oncol. 2016. PMID: 27046135 Free PMC article.
Background We characterized the incidence of central nervous system (CNS) involvement, risk factors and outcome in a large single institution dataset of peripheral T-cell lymphoma (PTCL). Methods Retrospective review of the PTCL database at Memorial Sloan Ket …
Background We characterized the incidence of central nervous system (CNS) involvement, risk factors and outcome in a large single institutio …
Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
Ye X, Fan X, Cui R, Mu J, Liu M, Lyu C, Li Y, Chen L, Zhang J, Li X, Wang J, Mou N, Deng Q. Ye X, et al. Ann Hematol. 2023 Jul;102(7):1789-1799. doi: 10.1007/s00277-023-05255-w. Epub 2023 May 12. Ann Hematol. 2023. PMID: 37171599
The clinical response and adverse events (AEs) in anti-CD19 CAR T cell therapy were observed. All patients with R/R FL who received BTK inhibitors combined with anti-CD19-CAR T cell therapy had later disease stages, higher tumor burden, and high …
The clinical response and adverse events (AEs) in anti-CD19 CAR T cell therapy were observed. All patients with R/R FL …
Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma.
Kim YR, Kim SJ, Cheong JW, Kim Y, Jang JE, Cho H, Chung H, Min YH, Yang WI, Cho A, Kim JS. Kim YR, et al. Korean J Intern Med. 2021 Mar;36(Suppl 1):S245-S252. doi: 10.3904/kjim.2019.376. Epub 2020 Jun 19. Korean J Intern Med. 2021. PMID: 32550718 Free PMC article.
Among the 78 patients with true positive results, the disease in seven (8.9%) had transformed to a different subtype. The positive predictive value (PPV) of FDG-PET/CT for aggressive B-cell non-Hodgkin's lymphoma (NHL) was lower than that for indolent B-cell …
Among the 78 patients with true positive results, the disease in seven (8.9%) had transformed to a different subtype. The positive …
39 results